Physician profile
Nanette Gabrielle Stein
NPI 1306311717
$6,136.78
in general payments reported to CMS, 2019-2025
30 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 94% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $719 · 2023: $1,438 · 2024: $1,562 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,792 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,792.19 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,296.02 | 2021-2025 | |
| Janssen Biotech, INC. | $607.86 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.49 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $323.01 | 2022-2025 | Entyvio, Gattex |
| Pfizer INC. | $255.98 | 2024-2025 | |
| Celgene Corporation | $227.57 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $221.47 | 2021-2025 | |
| Madrigal Pharmaceuticals | $220.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $206.19 | 2021-2023 | |
| Ardelyx, INC. | $200.24 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $194.17 | 2024-2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $131.68 | 2023-2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $124.58 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $112.77 | 2021-2023 | Sucraid |
| Alnylam Pharmaceuticals INC. | $105.63 | 2022-2023 | Givlaari |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $72.46 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $55.50 | 2021-2022 | |
| Daiichi Sankyo INC. | $54.55 | 2024 | Injectafer |
| Amgen INC. | $53.05 | 2023 | Amjevita, Avsola |
| Novo Nordisk INC | $50.91 | 2025 | Wegovy |
| Organon LLC | $42.58 | 2023-2024 | Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $38.68 | 2024 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.08 | 2023-2024 | Cyltezo, Jardiance |
| Redhill Biopharma INC. | $33.86 | 2021 | |
| Braintree Laboratories, INC. | $24.59 | 2023 | Sutab |
| Digestive Care, INC. | $22.57 | 2025 | Pertzye |
| Intercept Pharmaceuticals, INC. | $18.33 | 2021 | |
| Celltrion USA INC. | $17.76 | 2025 | Vegzelma |
| Sandoz INC. | $16.20 | 2024 | Hyrimoz |
| W. L. Gore & Associates, INC. | $14.59 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanette Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.